Core Insights - Anika Therapeutics reported a flat revenue of $30.6 million for Q4 2025 compared to Q4 2024, with a total revenue of $112.8 million for the full year, reflecting a 6% decrease from 2024 [2][3] - The company achieved a gross margin of 63% in Q4 2025, driven by a favorable product mix and operating leverage [2] - The Commercial Channel revenue grew by 22% in Q4 and 15% for the full year, while the OEM Channel revenue declined by 12% and 17% respectively [2][3] - Anika generated $11.2 million in operating cash flow and $4.4 million in free cash flow for the full year [3] Financial Performance - For Q4 2025, the company reported a GAAP income from continuing operations of $1.8 million, translating to $0.13 per diluted share [13] - The adjusted net income from continuing operations for Q4 was $4.6 million, or $0.31 per diluted share [13] - The full year 2025 saw a GAAP loss from continuing operations of $(10.0) million, or $(0.70) per diluted share [13] - Adjusted EBITDA for Q4 was $4.5 million, while for the full year it was $5.3 million [13] Business Highlights - The International OA Pain Management segment grew by 28% in Q4 and 12% for the full year, driven by regional expansion and improved market share [6] - The Integrity™ Implant System saw more than double the procedures in 2025, contributing to revenue growth of $6 million [6] - Anika is preparing responses for the FDA regarding the Hyalofast® PMA, with responses received in January 2026 [5][6] - The company has initiated actions to reduce general and administrative expenses, anticipating approximately $2.5 million in annualized adjusted EBITDA savings [7] 2026 Guidance - Anika provided guidance for 2026, projecting total revenue between $114 million and $122.5 million, representing a year-over-year increase of 1% to 9% [11] - The Commercial Channel is expected to generate revenue between $53 million and $58 million, maintaining a growth rate of 10% to 20% year over year [11] - The OEM Channel is projected to maintain flat to modestly lower revenue, between $61 million and $64.5 million [11]

Core Insights - Anika Therapeutics reported a 6% decrease in total revenue for Q3 2025, amounting to $27.8 million compared to the same period in 2024, while Commercial Channel revenue increased by 22% year over year [2][14] - The company reaffirmed its fiscal 2025 guidance and announced a $15 million share repurchase program [1][10] Financial Performance - Revenue from continuing operations was $27.8 million, down 6% from $29.6 million in Q3 2024 [2][14] - OEM Channel revenue decreased by 20% to $15.8 million, attributed to lower U.S. pricing for Monovisc and Orthovisc [2][14] - Commercial Channel revenue increased to $12.0 million, reflecting a 22% year-over-year growth [2][14] - Gross margin stood at 56%, with operating expenses down 3% to $18.8 million [14] Product Performance - Integrity procedures grew for the sixth consecutive quarter, with a projected doubling of procedures and revenue in 2025 compared to 2024 [4] - Cingal achieved a commercial milestone of over one million injections globally since its launch in 2016 [1][3] - International OA Pain Management revenue grew by 21% year over year, driven by distributor orders [5] Regulatory and Clinical Developments - Anika submitted the third and final module of the Hyalofast PMA application to the FDA, with positive clinical data released from the Phase III FastTRACK trial [6] - Progress was made towards filing the NDA for Cingal, with key activities including the completion of a toxicity study [7] Shareholder Returns - The company is commencing a $15 million 10b5-1 share repurchase program, expected to be completed by June 2026 [10]